[go: up one dir, main page]

AU2002225756A1 - Uses of mammalian genes and related reagents - Google Patents

Uses of mammalian genes and related reagents

Info

Publication number
AU2002225756A1
AU2002225756A1 AU2002225756A AU2575602A AU2002225756A1 AU 2002225756 A1 AU2002225756 A1 AU 2002225756A1 AU 2002225756 A AU2002225756 A AU 2002225756A AU 2575602 A AU2575602 A AU 2575602A AU 2002225756 A1 AU2002225756 A1 AU 2002225756A1
Authority
AU
Australia
Prior art keywords
mammalian genes
related reagents
reagents
mammalian
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225756A
Inventor
Bernhard Homey
Monica L. Zepeda
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2002225756A1 publication Critical patent/AU2002225756A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002225756A 2000-12-01 2001-11-27 Uses of mammalian genes and related reagents Abandoned AU2002225756A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25078200P 2000-12-01 2000-12-01
US60/250,782 2000-12-01
PCT/US2001/044338 WO2002043758A2 (en) 2000-12-01 2001-11-27 Uses of mammalian genes and related reagents

Publications (1)

Publication Number Publication Date
AU2002225756A1 true AU2002225756A1 (en) 2002-06-11

Family

ID=22949122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225756A Abandoned AU2002225756A1 (en) 2000-12-01 2001-11-27 Uses of mammalian genes and related reagents

Country Status (7)

Country Link
US (1) US20020111290A1 (en)
EP (1) EP1399184A2 (en)
JP (1) JP2004517078A (en)
AU (1) AU2002225756A1 (en)
CA (1) CA2430401A1 (en)
MX (1) MXPA03004913A (en)
WO (1) WO2002043758A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011624A (en) 2002-05-24 2005-03-07 Schering Corp Neutralizing human anti-igfr antibody.
ES2282666T3 (en) 2002-06-12 2007-10-16 Laboratoires Serono Sa CXC CHEMIOKIN ANTAGONISTS FROM UNION TO CXCR3.
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
EP1691199B1 (en) * 2003-10-01 2009-04-01 Shiseido Company Limited Method of predicting spot formation on the skin with the use of spot site-accelerating genes as indication and method of screening inhibitor for spot formation on the skin
CN1938428A (en) 2003-11-12 2007-03-28 先灵公司 Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1738175A2 (en) * 2004-03-22 2007-01-03 Novartis AG Chemokine ccl18 as a biomarker
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
EP1803464A4 (en) * 2004-09-17 2009-09-09 Cellgentech Inc External preparation for treating skin ulcer
JP2008521907A (en) 2004-12-03 2008-06-26 シェーリング コーポレイション Biomarkers for preselecting patients for anti-IGF1R treatment
US20070141627A1 (en) * 2005-10-19 2007-06-21 Behrens Timothy W Systemic Lupus Erythematosus
WO2007077257A2 (en) * 2006-01-05 2007-07-12 Galderma Research & Development Acne lesions biomarkers and modulators thereof
GB0607774D0 (en) * 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2142206B1 (en) * 2007-03-30 2014-07-30 The Cleveland Clinic Foundation SDF-1 for use in the treatment of ischemic peripheral vascular disorders
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
KR101000608B1 (en) 2007-11-19 2010-12-10 (주)아모레퍼시픽 Black mushroom outbreak diagnostic kit and how to diagnose black mushroom outbreak
WO2009079451A2 (en) * 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
JP2012233693A (en) * 2009-08-26 2012-11-29 Sapporo Medical Univ Examination method of host versus graft disease
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2566500B1 (en) 2010-05-05 2017-04-12 Rappaport Family Institute for Research in the Medical Sciences Ccl1 for use in therapy
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
EP2717894B1 (en) 2011-06-07 2018-01-24 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CN104520323B (en) 2012-03-02 2018-05-04 瓦西尼斯公司 Method for the inflammatory disease for treating B cell mediation
JP6363623B2 (en) 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド Method for increasing the level of immunoglobulin A
WO2015147335A1 (en) * 2014-03-27 2015-10-01 国立大学法人大阪大学 Diagnosis and treatment of cerebral malaria
KR102152637B1 (en) * 2014-07-31 2020-09-08 (주)아모레퍼시픽 Composition for skin whitening containing a chemokine
SG10201606949QA (en) 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders
EP3312608B1 (en) * 2016-10-24 2019-10-02 Akribes Biomedical GmbH Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound
US20230304091A1 (en) * 2020-08-10 2023-09-28 Cutis Biomedical Research Center Minimally invasive kit for diagnosing skin condition, comprising microneedle patch

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981230A (en) * 1994-08-23 1999-11-09 Human Genome Sciences, Inc. Polynucleotide encoding chemokine β-4
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
PL318594A1 (en) * 1995-06-07 1997-06-23 Icos Corp Chemokine and analogues thereof originating from macrophages
JPH09249570A (en) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd Benzodiazepine-containing chemokine receptor antagonist
JPH09255572A (en) * 1996-03-26 1997-09-30 Takeda Chem Ind Ltd Medicine for antagonizing chemokine receptor
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
AR015425A1 (en) * 1997-09-05 2001-05-02 Smithkline Beecham Corp BENZOTIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE FOR PREPARATION, INTERMEDIARY COMPOUNDS AND PROCEDURE FOR PREPARATION
JP4314742B2 (en) * 1997-09-16 2009-08-19 東レ株式会社 CC chemokine production inhibitor
US6245332B1 (en) * 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6248755B1 (en) * 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity

Also Published As

Publication number Publication date
WO2002043758A3 (en) 2003-12-11
WO2002043758A2 (en) 2002-06-06
MXPA03004913A (en) 2003-09-05
EP1399184A2 (en) 2004-03-24
CA2430401A1 (en) 2002-06-06
JP2004517078A (en) 2004-06-10
US20020111290A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
AU2002225756A1 (en) Uses of mammalian genes and related reagents
AU2001278076A1 (en) Bstp-5 proteins and related reagents and methods of use thereof
AU2001274920A1 (en) Mammalian receptor proteins; related reagents and methods
AU2001292617A1 (en) Mammalian receptor genes and uses
AU2002214126A1 (en) Genetic analysis of microorganisms
AU3873200A (en) Mammalian cytokines; related reagents and methods
AU2001278011A1 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001269039A1 (en) Immobilized nucleic acids and uses thereof
AU2088801A (en) Metastasis genes and uses thereof
AU2002256108A1 (en) Synthesis and use of glycodendrimer reagents
AU7962398A (en) Mammalian genes; related reagents
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU6951300A (en) Novel uses of mammalian ccr6 receptors and related reagents
AU2001233212A1 (en) Mammalian cytokines; receptors; related reagents and methods
AU2001288985A1 (en) Uses of mammalian genes and related reagents
AU2001280891A1 (en) Uses of mammalian genes and related reagents
AU2001236802A1 (en) Novel uses of mammalian ccr8 receptors and related reagents
AU2001279164A1 (en) Mammalian dna binding membrane-associated protein-encoding gene and uses
AU3063699A (en) Isolated mammalian membrane protein genes and related reagents
AU1604701A (en) Mammalian genes; related reagents and methods
AU4341300A (en) Novel uses of mammalian ox2 protein and related reagents
AU2001249929A1 (en) Fdrg proteins and nucleic acid molecules and uses therefor
AU2002326808A1 (en) Mammalian genes; related reagents
AU5617200A (en) Nodavirus-based dna expression vector and uses thereof
AU2002249789A1 (en) Methods and reagents for analysis of rna structure and function